Zacks Research Upgrades Nutex Health (NASDAQ:NUTX) to “Strong-Buy”

Nutex Health (NASDAQ:NUTX) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other analysts have also commented on NUTX. B. Riley Financial started coverage on shares of Nutex Health in a research note on Friday, June 26th. They set a “buy” rating and a $290.00 price target for the company. Weiss Ratings upgraded Nutex Health from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, July 28th. Lake Street Capital reissued a “buy” rating and issued a $310.00 price target (up from $235.00) on shares of Nutex Health in a research report on Tuesday, August 11th. Finally, Wall Street Zen cut Nutex Health from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $300.00.

Nutex Health Stock Up 0.3%

NUTX stock opened at $188.10 on Monday. The stock’s 50 day simple moving average is $168.99 and its 200 day simple moving average is $131.92. The company has a market cap of $1.29 billion, a P/E ratio of 7.39 and a beta of 0.24. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.96 and a current ratio of 5.00. Nutex Health has a fifty-two week low of $77.21 and a fifty-two week high of $204.00.

Nutex Health (NASDAQ:NUTX) last announced its quarterly earnings data on Thursday, August 6th. The company reported $9.38 EPS for the quarter, beating analysts’ consensus estimates of $4.95 by $4.43. Nutex Health had a return on equity of 39.74% and a net margin of 21.25%.The firm had revenue of $210.75 million during the quarter, compared to analysts’ expectations of $215.03 million. On average, research analysts expect that Nutex Health will post 30.11 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nutex Health

Hedge funds and other institutional investors have recently modified their holdings of the business. Hussman Strategic Advisors Inc. purchased a new stake in Nutex Health during the fourth quarter worth about $3,457,000. Quantinno Capital Management LP purchased a new position in Nutex Health in the first quarter valued at about $843,000. First Trust Advisors LP boosted its stake in Nutex Health by 60.0% in the first quarter. First Trust Advisors LP now owns 18,335 shares of the company’s stock valued at $1,743,000 after acquiring an additional 6,874 shares during the last quarter. Empowered Funds LLC bought a new position in shares of Nutex Health during the 1st quarter valued at approximately $3,084,000. Finally, SG Americas Securities LLC increased its stake in shares of Nutex Health by 3,232.6% during the 1st quarter. SG Americas Securities LLC now owns 30,360 shares of the company’s stock worth $2,885,000 after purchasing an additional 29,449 shares during the last quarter. Hedge funds and other institutional investors own 5.32% of the company’s stock.

Nutex Health Company Profile

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.